Patents by Inventor Tielin Zhou
Tielin Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12098204Abstract: The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy.Type: GrantFiled: November 15, 2019Date of Patent: September 24, 2024Assignee: Nanjing Genscript Biotech Co., Ltd.Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu
-
Patent number: 12037396Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.Type: GrantFiled: July 25, 2019Date of Patent: July 16, 2024Assignee: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu
-
Publication number: 20230125301Abstract: The present application provides multispecific constructs that bind to Claudin-18.2 (such as various anti-Claudin-18.2Ă—anti-PD-L1 bispecific antibodies), nucleic acids encoding the multispecific construct or a portion thereof, vectors comprising the nucleic acids, host cells containing the vectors, methods of preparing the multispecific constructs, pharmaceutical compositions comprising any of the multispecific constructs, and methods of using the multispecific constructs or compositions.Type: ApplicationFiled: January 19, 2021Publication date: April 27, 2023Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Zhongdao Li, Liusong Yin, Tielin Zhou, Zhuo Fang, Yi Jin
-
Publication number: 20230093512Abstract: The present application provides fusion proteins that have a TGF? superfamily receptor ectodomain (such as fusion proteins that have a TGF? superfamily receptor ectodomain and bind to PD-L1), nucleic acids encoding the fusion protein or a portion thereof, vectors comprising the nucleic acids, host cells containing the vectors, methods of preparing the fusion proteins, pharmaceutical compositions comprising any of the fusion proteins, and methods of using the fusion proteins or compositions.Type: ApplicationFiled: February 18, 2021Publication date: March 23, 2023Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Zhongdao Li, Liusong Yin, Tielin Zhou, Tianhui Xia, Zhuo Fang, Yi Jin
-
Publication number: 20220332848Abstract: The present invention relates to an anti-CD47/anti-CTLA-4 bispecific antibody and a preparation method thereof and an application thereof. The bispecific antibody comprises (a) a first antigen-binding portion, comprising a heavy chain variable region (VH) and a light chain variable region (VL), where VH and VL form an antigen-binding site that specifically binds to CD47; and (b) a second antigen-binding portion comprising a single domain antibody (sdAb) that specifically binds to CTLA-4, the first antigen-binding portion and the second antigen-binding portion are fused to each other. The bispecific antibody to which the present invention relates may simultaneously block two means of tumor immune escape, and therefore has a better effect in tumor immunotherapy.Type: ApplicationFiled: July 16, 2020Publication date: October 20, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Zhongdao Li, Tielin Zhou, Zhuo Fang
-
Publication number: 20220332824Abstract: The present invention relates to an anti-CD47/anti-PD-1 bispecific antibody, preparation method thereof and use thereof. The bispecific antibody includes (a) a first antigen binding portion including a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and VL form an antigen binding site that specifically binds to CD47; and (b) a second antigen binding portion including a single-domain antibody (sdAb) that specifically binds to PD-1, wherein the first antigen binding portion and the second antigen binding portion are fused with each other. The bispecific antibody of the present invention can block two manners of tumor immune escape simultaneously, and thus, has a good effect in tumor immunotherapy.Type: ApplicationFiled: July 8, 2020Publication date: October 20, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Zhongdao Li, Tielin Zhou, Zhuo Fang
-
Publication number: 20220289848Abstract: The present application provides multiple antigen binding proteins containing a first antigen binding portion that specifically binds an epitope on CD47, preferably human CD47, and a second antigen binding portion that specifically binds an epitope on programmed death-ligand 1 (PD-L1). Also provided are nucleic acids encoding the multiple antigen binding proteins, vectors comprising the nucleic acids, host cells comprising the vectors, and pharmaceutical compositions comprising the multiple antigen binding proteins, as well as methods for treating cancer using the multiple antigen binding proteins and pharmaceutical compositions.Type: ApplicationFiled: May 18, 2020Publication date: September 15, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Zhongdao Li, Tielin Zhou, Zhuo Fang
-
Publication number: 20220267436Abstract: Disclosed are an anti-CD47/anti-LAG-3 bispecific antibody, a preparation method thereof and a use thereof. The bispecific antibody comprises (a) a first antigen binding portion, which comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and VL form an antigen binding site for specifically binding to CD47; and (b) a second antigen binding portion, which comprises a single-domain antibody (sdAb) for specifically binding to LAG-3, wherein the first antigen binding portion and the second antigen binding portion fuse with each other. The bispecific antibody can simultaneously block two modes of tumor immune escape, thus providing a better effect in tumor immunotherapy.Type: ApplicationFiled: July 23, 2020Publication date: August 25, 2022Inventors: Liusong Yin, Zhongdao Li, Tielin Zhou, Zhuo Fang
-
Publication number: 20220267475Abstract: Anti-CD47/anti-TIGIT bispecific antibody, a preparation method thereof and application thereof. The bispecific antibody comprises: (a) a first antigen binding part, comprising heavy chain variable region (VH) and light chain variable region (VL), VH and VL forming an antigen binding site that specifically binds to CD47; and (b) a second antigen binding part, comprising a single domain antibody (sdAb) that specifically binds to TIGIT, wherein the first antigen binding part and the second antigen binding part are fused with each other. The bispecific antibody can block two modes of tumor immune escape at the same time, thus having a good effect in tumor immunotherapy.Type: ApplicationFiled: June 24, 2020Publication date: August 25, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Zhongdao Li, Tielin Zhou, Zhuo Fang
-
Publication number: 20220235133Abstract: Provided are a monoclonal antibody-cytokine fusion protein dimer and an application thereof. The monoclonal antibody comprises two heavy chains, the fusion protein dimer comprises a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, wherein one heavy chain of the monoclonal antibody is connected to a cytokine to form the first heavy chain polypeptide chain, and the other heavy chain of the monoclonal antibody is optionally connected to another cytokine to form the second heavy chain polypeptide chain. The monoclonal antibody-cytokine fusion protein dimer provided not only fully retains the biological activity of the antibody, but also significantly improves the biological activity of the cytokine(s). More importantly, by using the target specificity of the antibody molecule, the immune response of immune cells is enhanced and the toxicity of the cytokine(s) is reduced, and thus, on the premise of enhancing the efficacy of the drug, the safety of the medication is ensured.Type: ApplicationFiled: June 24, 2020Publication date: July 28, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Zhongdao Li, Liusong Yin, Zhenyu Liu, Tielin Zhou, Zhuo Fang
-
Publication number: 20220220204Abstract: The present application provides multiple antigen binding proteins containing a first antigen binding portion that specifically binds an epitope on PD-L1, preferably human PD-L1, and a second antigen binding portion that specifically binds an epitope on LAG-3. Also provided are nucleic acids encoding the multiple antigen binding proteins, vectors comprising the nucleic acids, host cells comprising the vectors, and pharmaceutical compositions comprising the multiple antigen binding proteins, as well as methods for treating cancer using the multiple antigen binding proteins and pharmaceutical compositions.Type: ApplicationFiled: June 12, 2020Publication date: July 14, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Zhongdao Li, Liusong Yin, Tielin Zhou, Zhuo Fang
-
Publication number: 20220119540Abstract: The present invention relates to a humanized anti-human OX40 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human OX40 monoclonal antibody provided in the present invention has high affinity and specificity for OX40, and can stimulate T cells to secrete cytokines, for example, specifically activate the positive immune regulation by OX40 and activate T cells to secrete cytokines. Therefore, the functional humanized anti-human OX40 monoclonal antibody provided in the present invention activates T cells by activating the OX40 signaling pathway, thereby achieving the purpose of tumor immunotherapy.Type: ApplicationFiled: November 26, 2019Publication date: April 21, 2022Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Tielin Zhou, Xinpo Jiang, Zhuo Fang, Yanling Mi, Chunchen Wu
-
Publication number: 20220073618Abstract: The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy.Type: ApplicationFiled: November 15, 2019Publication date: March 10, 2022Inventors: Liusong YIN, Tielin ZHOU, Zhuo FANG, Yanlirtg Ml, Chunchen WU
-
Publication number: 20220073643Abstract: Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells.Type: ApplicationFiled: December 27, 2019Publication date: March 10, 2022Applicants: Nanjing GenScript Biotech Co., Ltd., Nanjing Legend Biotech Co., Ltd.Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yong Liu, Qiuchuan Zhuang, Bo Wu, Xiaohu Fan, Qingshan Zhang, Dan Zhao, Jie Mao
-
Publication number: 20210301021Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.Type: ApplicationFiled: July 25, 2019Publication date: September 30, 2021Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu